• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: a meta-analysis of outcome trials
Direct oral anticoagulants (DOACs) are gradually replacing warfarin in the treatment of non-valvular atrial fibrillation because outcome comparison trials were constantly associated with a reduction of 1) stroke or systemic embolism events, and 2) major bleeding events [1 –4]. Whether the beneficial effect of DOACs vs warfarin on fatal and non-fatal outcomes is consistent to patients with or without diabetes mellitus (DM) has been previously approached by meta-analyses of the available outcome trials [5–7], in which no differential outcome effect was noticed.
Source: Diabetes Research and Clinical Practice - November 15, 2021 Category: Endocrinology Authors: Sotirios Drogkaris, Costas Thomopoulos, Theodoros Kalos, Eleni Manta, Costas Tsioufis Source Type: research

Use of non ‐vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus
ConclusionsThe efficacy and safety of non‐vitamin K oral anticoagulants compared with warfarin generally extend to participants with diabetes mellitus, although dedicated randomized trials or real‐world data are lacking.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - February 13, 2018 Category: Endocrinology Authors: O. Itzhaki, B. Zadok, A. Eisen Tags: Review Source Type: research

Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study ‐level meta‐analysis of phase III randomized trials
In this study‐level meta‐analysis, we included 4 randomized phase III trials comparing NOACs and warfarin in patients with nonvalvular AF; a total of 18 134 patients with DM and 40 454 without DM were overall considered. Incidence of the following outcome measures was evaluated during the follow‐up: stroke or systemic embolism, ischemic stroke, major bleeding, intracranial bleeding, and vascular death. Use of NOACs compared with warfarin reduced stroke/systemic embolism in diabetic (Risk Ratios [RR] 0.80, 95% CI 0.68‐0.93; P = .004) and nondiabetic patients (RR 0.83, 0.73‐0.93; P = .001) (P for interaction ...
Source: Diabetes/Metabolism Research and Reviews - January 26, 2017 Category: Endocrinology Authors: Giuseppe Patti, Giuseppe Di Gioia, Ilaria Cavallari, Antonio Nenna Tags: REVIEW ARTICLE Source Type: research

Safety and efficacy of non ‐vitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study‐level meta‐analysis of phase III randomized trials
ConclusionsResults of this meta‐analysis support the safety and efficacy of NOACs compared with warfarin in diabetic patients with non‐valvular AF.
Source: Diabetes/Metabolism Research and Reviews - October 31, 2016 Category: Endocrinology Authors: Giuseppe Patti, Giuseppe Di Gioia, Ilaria Cavallari, Antonio Nenna Tags: REVIEW ARTICLE Source Type: research